Literature DB >> 10700538

Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype.

V Dubowitz1.   

Abstract

The classical form of severe spinal muscular atrophy (SMA type 1; Werdnig-Hoffmann disease) has a very consistent clinical phenotype that is well recognized by paediatricians. It usually presents at birth or within the first few months of life. There is general hypotonia, with axial and limb weakness; the legs are affected more than the arms and proximal muscles more than distal, leaving residual spontaneous activity in the feet and in the forearms and hands. Facial muscles are spared so that the infant usually has a bright normal expression. The intercostal muscles are always affected, whereas the diaphragm is spared, allowing adequate spontaneous respiratory activity until the infants are precipitated into respiratory failure by an incidental respiratory infection, or aspiration. With rare exception they die by 2 years of age with a median around 7 months and with about 80% of the children dying by the time they are 1 year old. There is a consistent homozygous deletion in exons 7 and 8 of the telomeric copy of the survival motor neuron (SMN) gene. In the current issue of the journal, MacLeod and her colleagues have documented five cases of more severe spinal muscular atrophy, with a history of diminished fetal movements in utero and presenting at birth with asphyxia and severe weakness. Copyright 1999 European Paediatric Neurology Society.

Entities:  

Mesh:

Year:  1999        PMID: 10700538     DOI: 10.1053/ejpn.1999.0181

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  42 in total

1.  Low levels of Survival Motor Neuron protein are sufficient for normal muscle function in the SMNΔ7 mouse model of SMA.

Authors:  Chitra C Iyer; Vicki L McGovern; Jason D Murray; Sara E Gombash; Phillip G Zaworski; Kevin D Foust; Paul M L Janssen; Arthur H M Burghes
Journal:  Hum Mol Genet       Date:  2015-08-13       Impact factor: 6.150

Review 2.  Developing therapies for spinal muscular atrophy.

Authors:  Mary H Wertz; Mustafa Sahin
Journal:  Ann N Y Acad Sci       Date:  2015-07-14       Impact factor: 5.691

Review 3.  Spinal muscular atrophy: state of the art and new therapeutic strategies.

Authors:  Sonia Messina; Maria Sframeli; Lorenzo Maggi; Adele D'Amico; Claudio Bruno; Giacomo Comi; Eugenio Mercuri
Journal:  Neurol Sci       Date:  2021-04-19       Impact factor: 3.307

4.  Characterization of behavioral and neuromuscular junction phenotypes in a novel allelic series of SMA mouse models.

Authors:  Melissa Osborne; Daniel Gomez; Zhihua Feng; Corissa McEwen; Jose Beltran; Kim Cirillo; Bassem El-Khodor; Ming-Yi Lin; Yun Li; Wendy M Knowlton; David D McKemy; Laurent Bogdanik; Katherine Butts-Dehm; Kimberly Martens; Crystal Davis; Rosalinda Doty; Keegan Wardwell; Afshin Ghavami; Dione Kobayashi; Chien-Ping Ko; Sylvie Ramboz; Cathleen Lutz
Journal:  Hum Mol Genet       Date:  2012-07-16       Impact factor: 6.150

Review 5.  Spinal Muscular Atrophy.

Authors:  Stephen J Kolb; John T Kissel
Journal:  Neurol Clin       Date:  2015-11       Impact factor: 3.806

Review 6.  Spinal muscular atrophy: diagnosis and management in a new therapeutic era.

Authors:  W David Arnold; Darine Kassar; John T Kissel
Journal:  Muscle Nerve       Date:  2014-12-16       Impact factor: 3.217

7.  Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy.

Authors:  Ferrill F Rose; Virginia B Mattis; Hansjörg Rindt; Christian L Lorson
Journal:  Hum Mol Genet       Date:  2008-12-12       Impact factor: 6.150

8.  Mechanisms of ventilator dependence in children with neuromuscular and respiratory control disorders identified by monitoring diaphragm electrical activity.

Authors:  Miriam R Fine-Goulden; Naga K Puppala; Andrew Durward
Journal:  Intensive Care Med       Date:  2012-10-24       Impact factor: 17.440

9.  Mutations in mRNA export mediator GLE1 result in a fetal motoneuron disease.

Authors:  Heidi O Nousiainen; Marjo Kestilä; Niklas Pakkasjärvi; Heli Honkala; Satu Kuure; Jonna Tallila; Katri Vuopala; Jaakko Ignatius; Riitta Herva; Leena Peltonen
Journal:  Nat Genet       Date:  2008-01-20       Impact factor: 38.330

10.  U1A regulates 3' processing of the survival motor neuron mRNA.

Authors:  Eileen Workman; Alex Veith; Daniel J Battle
Journal:  J Biol Chem       Date:  2013-12-20       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.